Gini Fleming

17PUBLICATIONS
100CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsCommunication studies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 24, 2026
Ovarian cancer cell glucocorticoid receptor activation increases myeloid-derived suppressor cell tumor infiltration.

Manisha Taya, Eleanore Gray, Tryambak Srivastava

|Jan 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials.

Stephen J Luen, Lauren C Brown, Courtney T van Geelen

|Jun 23, 2024
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.

Manisha Taya, Xiaonan Hou, Jennifer T Veneris

|Oct 05, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.

Linda R Duska, Dmitriy Zamarin, Erica Hamilton

|Jun 26, 2023
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.

Nicoletta Colombo, Toon Van Gorp, Ursula A Matulonis

|Dec 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.

Olivia Pagani, Barbara A Walley, Gini F Fleming

Pageof 3

Frequent Collaborators

3 joint publications

Prudence A Francis

3 joint publications

Alan S Coates

3 joint publications

Meredith M Regan

3 joint publications

Sherene Loi